2. Search Result
Search Result
Results for "

liver fat

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

1

Biochemical Assay Reagents

2

Peptides

15

Natural
Products

6

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-143712
    Allolithocholic acid
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Allolithocholic acid is a steroid acid could found in normal serum and feces. Allolithocholic acid facilitates excretion, absorption, and transport of fats and sterols in the intestine and liver .
    Allolithocholic acid
  • HY-145632A
    Pemvidutide TFA

    ALT-801 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
    Pemvidutide TFA
  • HY-N0324A
    Cholic acid sodium
    Maximum Cited Publications
    12 Publications Verification

    Sodium cholate

    		 Endogenous Metabolite Metabolic Disease
    Cholic acid sodium is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid sodium is orally active .
    Cholic acid sodium
  • HY-N0324
    Cholic acid
    Maximum Cited Publications
    12 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .
    Cholic acid
  • HY-N0324S
    Cholic acid-d4
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Cholic acid-d4 is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
    Cholic acid-d4
  • HY-N0324S1
    Cholic acid-d5

    		Endogenous Metabolite Metabolic Disease
    Cholic acid-d5 is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
    Cholic acid-d5
  • HY-N0324S2
    Cholic acid-13C

    		Endogenous Metabolite Metabolic Disease
    Cholic acid- 13C is the 13C-labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
    Cholic acid-13C
  • HY-P2032
    Cyclochlorotine

    		Endogenous Metabolite Infection Cancer
    Cyclochlorotine is a mycotoxin that can be extracted from the yellow rice infectant Penicillium islandicum Sopp. Cyclochlorotine promotes glycogenolysis, inhibits glycogen synthesis, affects fat synthesis and protein synthesis in liver cells. Cyclochlorotine exhibits chronic toxicity in liver that induces liver fibrosis and cirrhosis in mouse models. Cyclochlorotine exhibits carcinogenicity .
    Cyclochlorotine
  • HY-168468
    SKLB102

    		PPAR Metabolic Disease
    SKLB102 shows a high affinity with PPARγ. SKLB102 has potent ability to reduce fat deposition and protect liver against non-alcoholic fatty liver disease (NAFLD) through regulating adipocytokine expression and preventing insulin resistance .
    SKLB102
  • HY-N0324B
    Cholic acid sodium hydrate

    		Endogenous Metabolite Metabolic Disease
    Cholic acid sodium hydrate is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. Cholic acid sodium hydrate facilitates fat absorption and cholesterol excretion. Cholic acid sodium hydrate is orally active .
    Cholic acid sodium hydrate
  • HY-155525
    Anti-NASH agent 1

    		PPAR Metabolic Disease Inflammation/Immunology
    Anti-NASH agent 1 (compound 3d)，a derivative of Elafibranor (HY-16737)，is a potent agonist of PPAR-α/δ，targeting to nonalcoholic steatohepatitis (NASH). Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves hyperlipidemia，liver fat degeneration and liver inflammation in Methionine-choline deficiency (MCD) induced NASH mice model. Anti-NASH agent 1 shows low liver toxicity and potent liver protection effect .
    Anti-NASH agent 1
  • HY-N0723
    Neomangiferin

    		Others Metabolic Disease
    Neomangiferin is a natural C-glucosyl xanthone isolated from m the dried rhizome of Anemarrhena asphodeloides. Neomangiferin has significant therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in rats .
    Neomangiferin
  • HY-N7515
    Pinocembrin chalcone

    2',4',6'-Trihydroxychalcone

    		 Bacterial AMPK Infection Metabolic Disease Inflammation/Immunology
    Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an antibacterial compound from Helichrysum Trilineatum. Pinocembrin chalcone facilitates AMP-activated protein kinase (AMPK) activation, improves glucose tolerance, increases muscle FAO and reduces fat accumulation in the liver and skeletal muscles in high-fat diet-induced (HFD) diabetic mice. Pinocembrin chalcone is promising for research of gastric ulcers and diabetes .
    Pinocembrin chalcone
  • HY-19796
    Icomidocholic acid
    1 Publications Verification

    Aramchol; C20-FABAC

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .
    Icomidocholic acid
  • HY-159595
    PCSK9-IN-29

    		LDLR PCSK9 Metabolic Disease Inflammation/Immunology
    PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
    PCSK9-IN-29
  • HY-101397R
    Allopurinol riboside (Standard)

    		Parasite Drug Metabolite Endogenous Metabolite Infection
    Cholic acid (Standard) is the analytical standard of Cholic acid. This product is intended for research and analytical applications. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .
    Allopurinol riboside (Standard)
  • HY-N0324R
    Cholic acid (Standard)
    Maximum Cited Publications
    12 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Cholic acid (Standard) is the analytical standard of Cholic acid. This product is intended for research and analytical applications. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .
    Cholic acid (Standard)
  • HY-128135
    MHY 553

    		PPAR Inflammation/Immunology
    MHY 553 is a PPARα agonist that is effective when taken orally. MHY 553 helps alleviate liver fat accumulation by increasing fatty acid oxidation and reducing inflammation during the aging process. MHY 553 inhibits the accumulation of triglycerides induced by liver X receptor agonists in HepG2 cells. MHY 553 significantly suppresses the expression of inflammatory mRNA in aging rats .
    MHY 553
  • HY-N2334AS
    Glycochenodeoxycholic acid-d7 sodium

    Chenodeoxycholylglycine-d7 (sodium); Sodium glycochenodeoxycholate-d7

    		 Endogenous Metabolite Apoptosis Cancer
    Glycochenodeoxycholic acid-d7 (sodium) is the deuterium labeled Glycochenodeoxycholic acid (sodium salt). Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) induces hepatocyte apoptosis[1][2].
    Glycochenodeoxycholic acid-d7 sodium
  • HY-N0324AR
    Cholic acid sodium (Standard)

    Sodium cholate (Standard)

    		 Endogenous Metabolite Metabolic Disease
    Cholic acid (sodium) (Standard) is the analytical standard of Cholic acid (sodium). This product is intended for research and analytical applications. Cholic acid sodium is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid sodium is orally active[1][2].
    Cholic acid sodium (Standard)
  • HY-N2334S
    Glycochenodeoxycholic acid-d4

    Chenodeoxycholylglycine-d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Cancer
    Glycochenodeoxycholic acid-d4 is the deuterium labeled Glycochenodeoxycholic acid. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) induces hepatocyte apoptosis[1][2].
    Glycochenodeoxycholic acid-d4
  • HY-N0324F
    Cholic acid-Biotin

    		Fluorescent Dye Metabolic Disease
    Cholic acid-Biotin is a biotin-labeled Cholic acid (HY-N0324). Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid has orally activity .
    Cholic acid-Biotin
  • HY-N14035
    Garcinia cambogia extract

    		ATP Citrate Lyase Cardiovascular Disease Metabolic Disease
    Garcinia cambogia extract contains several active compounds, including hydroxycitric acid (HCA) (an ECC inhibitor), xanthones, benzophenones, hydroxycitric acid (an ATP-citrate lyase inhibitor). Garcinia cambogia extract lowers the body weight gain, visceral fat accumulation, blood and hepatic lipid concentrations, and plasma insulin and leptin levels in a high-fat diet (HFD)-induced obesity mouse model. Garcinia cambogia extract is promising for research of fatty liver, dyslipidemia, hyperinsulinemia and hyperleptinemia rendered by HFD .
    Garcinia cambogia extract
  • HY-161985
    PPARγ-IN-3

    		PPAR Metabolic Disease
    PPARγ-IN-3 (compound 9ga) is a potent and orally active PPARγ inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity .
    PPARγ-IN-3
  • HY-N0723R
    Neomangiferin (Standard)

    		Others Metabolic Disease
    Neomangiferin (Standard) is the analytical standard of Neomangiferin. This product is intended for research and analytical applications. Neomangiferin is a natural C-glucosyl xanthone isolated from m the dried rhizome of Anemarrhena asphodeloides. Neomangiferin has significant therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in rats .
    Neomangiferin (Standard)
  • HY-147246
    Berberine ursodeoxycholate
    1 Publications Verification

    HTD1801; BUDCA

    		 Biochemical Assay Reagents Metabolic Disease
    Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .
    Berberine ursodeoxycholate
  • HY-168046
    ALG-055009

    		Thyroid Hormone Receptor Metabolic Disease
    ALG-055009 is a thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.063 μM. In rats on a high-fat diet, ALG-055009 can lower total cholesterol levels. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease .
    ALG-055009
  • HY-N2181
    Acetylshikonin
    1 Publications Verification

    		 Cytochrome P450 Apoptosis Bacterial Autophagy Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC50=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD) .
    Acetylshikonin
  • HY-12756A
    E6446 dihydrochloride
    1 Publications Verification

    		 Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD) Metabolic Disease Inflammation/Immunology
    E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
    E6446 dihydrochloride
  • HY-12756
    E6446
    1 Publications Verification

    		 Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD) Metabolic Disease Inflammation/Immunology
    E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
    E6446
  • HY-143712S1
    Allolithocholic Acid-d4

    3α-hydoxy-5α-Cholaoic Acid-d4, allo-LCA-d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Allolithocholic Acid-d4 (3α-hydoxy-5α-Cholaoic Acid-d4, allo-LCA-d4) is deuterium labeled Allolithocholic acid. Allolithocholic acid is a steroid acid could found in normal serum and feces. Allolithocholic acid facilitates excretion, absorption, and transport of fats and sterols in the intestine and liver .
    Allolithocholic Acid-d4
  • HY-143712R
    Allolithocholic acid (Standard)

    		Endogenous Metabolite Metabolic Disease
    Dexamethasone metasulfobenzoate (sodium) (Standard) is the analytical standard of Dexamethasone metasulfobenzoate (sodium). This product is intended for research and analytical applications. Dexamethasone metasulfobenzoate sodium is a SARS-CoV-2 exonuclease (ExoN) inhibitor that binds to the catalytic site of ExoN .
    Allolithocholic acid (Standard)
  • HY-130437
    p-nitro-Pifithrin-α

    		MDM-2/p53 TGF-β Receptor Caspase Infection Metabolic Disease
    p-nitro-Pifithrin-α, a cell-permeable analog of pifithrin-α, is a potent p53 inhibitor. p-nitro-Pifithrin-α suppresses p53-mediated TGF-β1 expression in HK-2 cells. p-nitro-Pifithrin-α inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice fed a high-fat diet [4]. non-alcoholic fatty liver disease .
    p-nitro-Pifithrin-α
  • HY-D1168
    Oil Red O
    4 Publications Verification

    		 Fluorescent Dye Metabolic Disease
    Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses .
    Oil Red O
  • HY-N8518
    Malabaricone C
    1 Publications Verification

    		 Phospholipase p38 MAPK Apoptosis NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells .
    Malabaricone C
  • HY-W643167
    1,2,3-Tritridecanoylglycerol

    Glycerol Tritridecanoyl; 13:0 TAG; 13:0/13:0/13:0-TG

    		 Biochemical Assay Reagents Infection
    1,2,3-Tritridecanoyl glycerol is a synthetic triacylglycerol that contains tridecanoic acid in the sn-1, sn-2, and sn-3 positions. It has been used as a standard for the relative quantification of triacylglycerols in C. elegans fat stores. It has also been used as an internal standard for the quantification of triacylglycerols in the serum and liver of adult rat offspring receiving dietary conjugated linoleic acids during and after gestation.
    1,2,3-Tritridecanoylglycerol
  • HY-123986
    CTPI-2
    10+ Cited Publications

    		 Mitochondrial Metabolism Inflammation/Immunology Cancer
    CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity .
    CTPI-2
  • HY-133971
    Cholesterol 5α,6α-epoxide

    5α,6α-Epoxycholesterol

    		 Liposome Others
    Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.
    Cholesterol 5α,6α-epoxide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: